The disclosure relates to the use of clevidipine or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for reducing stroke damage in a subject with a stroke. The medicament may further comprise a lipid, an emulsifier, an antimicrobial agent, a tonicity modifier, an antioxidant, and a co-emulsifier.
